(7)Commission Directive 2008/125/ECnote included cymoxanil and tebuconazole in Annex I to Directive 91/414/EEC as active substances until 31 August 2019 and they were subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approvals of cymoxanil and tebuconazole were extended four and five times, respectively, most recently by Commission Implementing Regulation (EU) 2023/1446note until 15 August 2026.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.